Sean Callahan, MD
Family Medicine · Oak Harbor, OHNPI 1194811828
Payments from drug & device makers
Across 472 payments — averaging $15.58 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$911
- Boehringer Ingelheim$706
- Novo Nordisk$693
- AbbVie$676
- Lilly USA, LLC$546
- Pfizer$363
- plus $3K from 32 others
What the payments were for
- Food & beverage$7,355100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 47 | $911 |
| Boehringer Ingelheim | 39 | $706 |
| Novo Nordisk | 56 | $693 |
| AbbVie(2 entities) | 39 | $676 |
| Lilly USA, LLC | 36 | $546 |
| Pfizer | 33 | $363 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 25 | $337 |
| Amgen | 19 | $334 |
| Bayer | 15 | $244 |
| Johnson & Johnson | 16 | $232 |
| GSK | 15 | $225 |
| Merck | 15 | $214 |
| Takeda Pharmaceuticals U.S.A., Inc. | 13 | $191 |
| E.r. Squibb & Sons, L.L.C. | 9 | $149 |
| Biohaven Pharmaceuticals, Inc. | 10 | $142 |
| Novartis | 9 | $139 |
| Kowa Pharmaceuticals America, Inc. | 9 | $125 |
| Exact Sciences | 5 | $116 |
| Esperion Therapeutics, Inc. | 7 | $105 |
| Amarin Pharma, Inc. | 6 | $105 |
| Astellas Pharma US Inc | 7 | $103 |
| Otsuka America Pharmaceutical, Inc. | 5 | $99 |
| Eisai Inc. | 5 | $73 |
| Teva Pharmaceuticals USA, Inc. | 5 | $66 |
| Sanofi-aventis U.S. LLC | 4 | $66 |
| Idorsia Pharmaceuticals US Inc | 4 | $58 |
| Biohaven Pharmaceutical Holding Company Ltd. | 3 | $53 |
| Abbott | 2 | $39 |
| Pulmonx Corporation | 1 | $38 |
| Shield Therapeutics Inc | 2 | $34 |
| Lundbeck LLC | 2 | $30 |
| Almatica Pharma LLC | 2 | $29 |
| Phathom Pharmaceuticals, Inc. | 2 | $27 |
| Scilex Pharmaceuticals Inc. | 1 | $22 |
| Axsome Therapeutics, Inc. | 1 | $20 |
| Paratek Pharmaceuticals, Inc. | 1 | $16 |
| Biogen | 1 | $16 |
| Avanir Pharmaceuticals, Inc. | 1 | $13 |
How this compares
$7,355 in reported general payments places this provider in the 90th percentile of 3,983 family medicine providers in Ohio.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 213 | $109,325 |
| OzempicSemaglutide | 39 | $66,395 |
| JardianceEmpagliflozin | 53 | $47,380 |
| JanuviaSitagliptin Phosphate | 59 | $44,990 |
| XareltoRivaroxaban | 91 | $38,964 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 54 | $38,547 |
| TradjentaLinagliptin | 46 | $26,122 |
| MounjaroTirzepatide | 17 | $23,920 |
| MyrbetriqMirabegron | 32 | $18,544 |
| RexultiBrexpiprazole | 19 | $13,766 |
| JanumetSitagliptin Phos/Metformin Hcl | 12 | $9,183 |
| OxycontinOxycodone Hcl | 11 | $7,625 |
| Toujeo SolostarInsulin Glargine,hum.Rec.Anlog | 20 | $7,214 |
| VraylarCariprazine Hcl | 16 | $7,208 |
| LinzessLinaclotide | 11 | $7,159 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $363 | $109,325213 claims |
| Boehringer IngelheimJardiance, Tradjenta | $706 | $73,50299 claims |
| Novo NordiskOzempic | $693 | $66,39539 claims |
| MerckJanuvia, Janumet | $214 | $54,17371 claims |
| GSKTrelegy Ellipta, Breo Ellipta | $225 | $44,55869 claims |
| Johnson & JohnsonXarelto | $232 | $38,96491 claims |
| Lilly USA, LLCMounjaro | $546 | $23,92017 claims |
| AbbVieVraylar, Linzess, Restasis | $676 | $20,20744 claims |
| Astellas Pharma US IncMyrbetriq | $103 | $18,54432 claims |
| Otsuka America Pharmaceutical, Inc.Rexulti | $99 | $13,76619 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Trintellix | $191 | $4,61019 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 3,983 family medicine providers in Ohio.
Other family medicine in Oak Harbor
- Michael ButcherCincinnati$18.3M
- William RandallKettering$7.5M
- Paul NugentCincinnati$4.9M
- Steve ChoiDayton$4.8M
- Martin SchearDayton$2.2M
- Rajesh DavitCincinnati$2M
- Kwabena OtengSpringdale$2M
- Blaise GattoMoraine$1.8M
- Cathy GreiweColumbus$1.4M
- Brian BeesleyColumbus$1.4M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.